New strength variants of Favipiravir brands ‘PiFLU’ and ‘Favenza’ have been launched by FDC Limited. These drugs are used to treat mild to moderate cases of COVID-19 in India. The 800mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75%. Currently patients are required to take 18 pills on the first day followed by 8 tablets every day for the next 13 days. Drug Controller General of India (DCGI)-approved Favipiravir is a broad spectrum anti-viral agent and prevents viral replication. PiFLU and Favenza reduce progression to severe or critical conditions of COVID-19 in 92.5% of cases by Day 10, and 62.5% at Day 5. This oral anti-viral drug has been shown reducing the viral replication cycle leading to quicker clinical recovery in COVID-19 patients with mild to moderate symptoms. With innovations such as these, FDC continues to stand by India in its fight against COVID-19. These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from 1 November.
Related Posts
Sonia Gandhi Asks Congress-Ruled States To Override Centre’s Farm Laws.
The Congress on Monday said that its chief Sonia Gandhi has directed party governments in different states to “explore” and pass laws to “override” or negate the newly enacted central farm laws.Congress’s Rajya Sabha member KC Venugopal said in a…
Maharashtra political crisis
Shiv Sena MLA Dilip Lande arrived in Guwahati. Timeline of the political crisis in Maharashtra till 2 pm on Friday. Rebel Shiv Sena leader Eknath Shinde presides over a meeting of MLAs supporting him in Guwahati. Shinde claimed 50 MLAs,…
Assam DGP holds meeting with Madrasa
At Thrusadi, Assam Director General of Police (DGP) Bhaskar Jyoti Mahant held a meeting with State Director of Secondary Education Mamata Hojai along with representatives of five organizations including All Assam Tanjim Madaris Qawmia, All Assam Talimi Taraqi Board, Madrasa…